HCV in sickle cell disease

Mohamed Hassan, Syed Hasan, Oswaldo Castro, Samuel Giday, Alpha Banks, Duane Smoot

Research output: Contribution to journalArticle

Abstract

The sickle cell gene is common in the U.S. In fact 8% of African Americans are healthy carriers of the sickle cell trait (HbAS). People who are homozygous (HbSS) have severe disease. They have life-long anemia, chronic hemolysis, and also have at times hematological crises, which can worsen the anemia. Many patients require chronic transfusions and as a result, substantial proportions of sickle cell patients are at high risk for infection with blood-borne diseases - such as Hepatitis C Virus infection (HCV). The HCV antibody positivity is directly related to the number of transfusions given, and on average the prevalence rate in transfused patients is more than 10%. It is known that the combination of iron overload and HCV can lead to a more rapidly progressive liver disease. The treatment of HCV in sickle cell patients poses a challenge to clinicians. A novel approach described by some is the pre-treatment of these patients with hydroxyurea to increase the fetal hemoglobin, therefore decreasing the severity of Ribavirin-related hemolysis. Treatment with Peg-interferon, alone has not been used to treat HCV in sickle cell patients, but in the setting of controlled clinical trials it would be feasible. This review explores the impact of HCV in sickle cell patients and the possible therapeutic options available to them.

Original languageEnglish (US)
Pages (from-to)864-874
Number of pages11
JournalJournal of the National Medical Association
Volume95
Issue number9
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Virus Diseases
Hepacivirus
Hemolysis
Anemia
Sickle Cell Trait
Fetal Hemoglobin
Hepatitis C Antibodies
Iron Overload
Hydroxyurea
Hematologic Diseases
Ribavirin
Controlled Clinical Trials
Therapeutics
African Americans
Interferons
Liver Diseases
Infection
Genes

Keywords

  • Hepatitis C virus
  • Liver disease
  • Sickle cell disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hassan, M., Hasan, S., Castro, O., Giday, S., Banks, A., & Smoot, D. (2003). HCV in sickle cell disease. Journal of the National Medical Association, 95(9), 864-874.

HCV in sickle cell disease. / Hassan, Mohamed; Hasan, Syed; Castro, Oswaldo; Giday, Samuel; Banks, Alpha; Smoot, Duane.

In: Journal of the National Medical Association, Vol. 95, No. 9, 01.09.2003, p. 864-874.

Research output: Contribution to journalArticle

Hassan, M, Hasan, S, Castro, O, Giday, S, Banks, A & Smoot, D 2003, 'HCV in sickle cell disease', Journal of the National Medical Association, vol. 95, no. 9, pp. 864-874.
Hassan M, Hasan S, Castro O, Giday S, Banks A, Smoot D. HCV in sickle cell disease. Journal of the National Medical Association. 2003 Sep 1;95(9):864-874.
Hassan, Mohamed ; Hasan, Syed ; Castro, Oswaldo ; Giday, Samuel ; Banks, Alpha ; Smoot, Duane. / HCV in sickle cell disease. In: Journal of the National Medical Association. 2003 ; Vol. 95, No. 9. pp. 864-874.
@article{3586ed896bea47c38b443b12743868f9,
title = "HCV in sickle cell disease",
abstract = "The sickle cell gene is common in the U.S. In fact 8{\%} of African Americans are healthy carriers of the sickle cell trait (HbAS). People who are homozygous (HbSS) have severe disease. They have life-long anemia, chronic hemolysis, and also have at times hematological crises, which can worsen the anemia. Many patients require chronic transfusions and as a result, substantial proportions of sickle cell patients are at high risk for infection with blood-borne diseases - such as Hepatitis C Virus infection (HCV). The HCV antibody positivity is directly related to the number of transfusions given, and on average the prevalence rate in transfused patients is more than 10{\%}. It is known that the combination of iron overload and HCV can lead to a more rapidly progressive liver disease. The treatment of HCV in sickle cell patients poses a challenge to clinicians. A novel approach described by some is the pre-treatment of these patients with hydroxyurea to increase the fetal hemoglobin, therefore decreasing the severity of Ribavirin-related hemolysis. Treatment with Peg-interferon, alone has not been used to treat HCV in sickle cell patients, but in the setting of controlled clinical trials it would be feasible. This review explores the impact of HCV in sickle cell patients and the possible therapeutic options available to them.",
keywords = "Hepatitis C virus, Liver disease, Sickle cell disease",
author = "Mohamed Hassan and Syed Hasan and Oswaldo Castro and Samuel Giday and Alpha Banks and Duane Smoot",
year = "2003",
month = "9",
day = "1",
language = "English (US)",
volume = "95",
pages = "864--874",
journal = "Journal of the National Medical Association",
issn = "0027-9684",
publisher = "National Medical Association",
number = "9",

}

TY - JOUR

T1 - HCV in sickle cell disease

AU - Hassan, Mohamed

AU - Hasan, Syed

AU - Castro, Oswaldo

AU - Giday, Samuel

AU - Banks, Alpha

AU - Smoot, Duane

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The sickle cell gene is common in the U.S. In fact 8% of African Americans are healthy carriers of the sickle cell trait (HbAS). People who are homozygous (HbSS) have severe disease. They have life-long anemia, chronic hemolysis, and also have at times hematological crises, which can worsen the anemia. Many patients require chronic transfusions and as a result, substantial proportions of sickle cell patients are at high risk for infection with blood-borne diseases - such as Hepatitis C Virus infection (HCV). The HCV antibody positivity is directly related to the number of transfusions given, and on average the prevalence rate in transfused patients is more than 10%. It is known that the combination of iron overload and HCV can lead to a more rapidly progressive liver disease. The treatment of HCV in sickle cell patients poses a challenge to clinicians. A novel approach described by some is the pre-treatment of these patients with hydroxyurea to increase the fetal hemoglobin, therefore decreasing the severity of Ribavirin-related hemolysis. Treatment with Peg-interferon, alone has not been used to treat HCV in sickle cell patients, but in the setting of controlled clinical trials it would be feasible. This review explores the impact of HCV in sickle cell patients and the possible therapeutic options available to them.

AB - The sickle cell gene is common in the U.S. In fact 8% of African Americans are healthy carriers of the sickle cell trait (HbAS). People who are homozygous (HbSS) have severe disease. They have life-long anemia, chronic hemolysis, and also have at times hematological crises, which can worsen the anemia. Many patients require chronic transfusions and as a result, substantial proportions of sickle cell patients are at high risk for infection with blood-borne diseases - such as Hepatitis C Virus infection (HCV). The HCV antibody positivity is directly related to the number of transfusions given, and on average the prevalence rate in transfused patients is more than 10%. It is known that the combination of iron overload and HCV can lead to a more rapidly progressive liver disease. The treatment of HCV in sickle cell patients poses a challenge to clinicians. A novel approach described by some is the pre-treatment of these patients with hydroxyurea to increase the fetal hemoglobin, therefore decreasing the severity of Ribavirin-related hemolysis. Treatment with Peg-interferon, alone has not been used to treat HCV in sickle cell patients, but in the setting of controlled clinical trials it would be feasible. This review explores the impact of HCV in sickle cell patients and the possible therapeutic options available to them.

KW - Hepatitis C virus

KW - Liver disease

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=0141483820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141483820&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 864

EP - 874

JO - Journal of the National Medical Association

JF - Journal of the National Medical Association

SN - 0027-9684

IS - 9

ER -